Abstract:Rong Liu, 1, &ast Min Zhu, 2, &ast Jiaojiao Chen, 3 Junwei Gai, 2 Jing Huang, 2 Yingqun Zhou, 1 Yakun Wan, 2 Chuantao Tu 4 1 Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, People's Republic of China; 2 Shanghai Novamab Biopharmaceuticals Co., Ltd, Shanghai, 201318, People's Republic of China; 3 Department of Gastroenterology, Shanghai Fourth People's Hospital, Tongji University School of Medicine, Shanghai, 200434, People's Republic of China; 4 Department of Gastroenterology, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chuantao Tu; Yakun Wan, Email ; Background: No agents are currently available for the treatment or reversal of liver fibrosis. Novel antifibrotic therapies for chronic liver diseases are thus urgently needed. Connective tissue growth factor (CTGF) has been shown to contributes profoundly to liver fibrogenesis, which makes CTGF as a promising target for developing antifibrotic agents. Methods: In this study, we identified a novel nanobody (Nb) against human CTGF (anti-CTGF Nb) by phage display using an immunized camel, which showed high affinity and specificity in vitro. LX-2 cells, the immortalized human hepatic stellate cells, were induced by transforming growth factor beta1 (TGFβ 1) as an in vitro model of liver fibrosis to verify the antifibrotic activity of the anti-CTGF Nb. Results: Our data demonstrated that anti-CTGF Nb effectively alleviated TGFβ 1-induced LX-2 cell proliferation, activation, and migration, and promoted the apoptosis of activated LX-2 cells in response to TGFβ 1. Moreover, the anti-CTGF Nb remarkably reduced the levels of TGFβ 1, Smad2, and Smad3 expression in LX-2 stellate cells stimulated by TGFβ 1. Conclusion: Taken together, we successfully identified a novel Nb against human CTGF, which exhibited antifibrotic effects in vitro by regulating the biological functions of human stellate cells LX-2. Graphical Keywords: nanobody, connective tissue growth factor, liver fibrosis, hepatic stellate cells Graphical Chronic liver injury of various etiologies can lead to liver fibrosis characterized by excessive accumulation of extracellular matrix (ECM) in the liver. 1–3 If remain unresolved, liver fibrosis may progress to cirrhosis, liver failure, and even hepatocellular carcinoma (HCC). 1 Chronic fibrotic liver disease and cirrhosis represent a major global health challenge. However, there are currently no approved therapeutic agents to treat or reverse liver fibrosis. 1,2 Therefore, a deep understanding of molecular mechanisms underlying hepatic fibrogenesis is needed to identify potential targets for antifibrotic therapies. Hepatic stellate cells (HSCs) have been identified as the primary precursor cells of myofibroblasts (MFBs), which orchestrate the deposition of ECM in normal and fibrotic liver. 1–3 Upon liver injury, hepatocytes and nonparenchymal cells, such as Kupffer cells, endothelial cells, and neutrophil granulocytes, release cytokines and chemokines, ultimately activate HSCs to release their vitamin A and retinoid stores, and undergo dramatic phenotypic alterations, and transdifferentiate into MFBs. 1,3–5 Furthermore, the activated MFBs exhibit a variety of cellular processes such as proliferation, migration, contractility, and apoptosis resistance, accompanied by secretion of cytokines, chemokines, and ECM components. 4 Thus, targeting the activation of MFBs are emerging as a high potential a strategy for treating liver fibrosis. 1,6 Transforming growth factor beta (TGFβ) signaling is considered as a master profibrogenic pathway responsible for ECM production and plays a key role in the pathogenesis of liver fibrosis. 7–9 TGFβ1 is the principal isoform of TGFβ which mediates SMAD2/3 dependent pathway, commonly activating HSCs and stimulating the production of ECM synthesis. 7,8 Therefore, blocking TGFβ signaling represents an attractive antifibrotic therapy. 5,7 However, TGFβ is a multifunctional cytokine and has important roles in liver physiology, and its inhibition results in undesirable side effects, 5,7,10 which is a major challenge for translation into use of the clinic. Therefore, an improved understanding of the downstream regulatory mechanisms of TGF-β may help develop therapeutic strategies against liver fibrosis. 7 Connective tissue growth factor (CT -Abstract Truncated-

Expression, purification, and evaluation of in vivo anti-fibrotic activity for soluble truncated TGF-β receptor II as a cleavable His-SUMO fusion protein

Curcumin Inhibits Transforming Growth Factor-Beta Activity Via Inhibition of Smad Signaling in HK-2 Cells.

Development of a Chimeric Protein BiPPB-mIFNγ-tTβRII for Improving the Anti-Fibrotic Activity in Vivo by Targeting Fibrotic Liver and Dual Inhibiting the TGF-β1/Smad Signaling Pathway

TGF2 and TGF3 isoforms drive fibrotic disease pathogenesis

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

Bacterial expression and purification of biologically active human TFF2.

PDGFβ receptor-targeted delivery of truncated transforming growth factor β receptor type II for improving the in vitro and in vivo anti-renal fibrosis activity via strong inactivation of TGF-β1/Smad signaling pathway

Molecular cloning, in vitro expression and bioactivity of rabbit transforming growth factor-beta receptor type II (rTGF-βRII).

[Effects of Antisense Transforming Growth Factor Beta Receptor-Ii (tgfbetarii) Expressing Plasmid on Experimental Liver Fibrosis].

Oral delivery of a Lactococcus lactis expressing extracellular TGFβR2 alleviates hepatic fibrosis

A COL1A1 Promoter-Controlled Expression of TGF-β Soluble Receptor Inhibits Hepatic Fibrosis Without Triggering Autoimmune Responses

High-level expression and characterization of bioactive human truncated variant of hepatocyte growth factor in Escherichia coli

[Effects of Antisense Transforming Growth Factor Beta Receptor-I Expressing Plasmid on Pig Serum-Induced Rat Liver Fibrosis].

[Purification and Characterization of the Fusion Protein TGF-betaR II/Fc].

Blockage of Transforming Growth Factor Β Receptors Prevents Progression of Pig Serum-Induced Rat Liver Fibrosis

722. Silencing of Transforming Growth Factor-β Receptor II by RNA Interference Suppresses Extracellular Matrix Production in Rat Hepatic Stellate Cells

Engineering, Expression And Renaturation Of Targeted Tgf-Beta Fusion Proteins

Identification of a Novel TGF-β-miR-122-fibronectin 1/serum Response Factor Signaling Cascade and Its Implication in Hepatic Fibrogenesis

Identification and Characterization of a Novel Nanobody Against Human CTGF to Reveal Its Antifibrotic Effect in an in vitro Model of Liver Fibrosis

Design, Synthesis and Discovery of 2(1H)-Quinolone Derivatives for the Treatment of Pulmonary Fibrosis Through Inhibition of TGF-β/smad Dependent and Independent Pathway.

Heparan sulfate proteoglycans-mediated targeted delivery of TGF-β1-binding peptide to liver for improved anti-liver fibrotic activity in vitro and in vivo